TY - JOUR
T1 - International Evidence Based Reappraisal of Genes Associated with Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework
AU - James, Cynthia A
AU - Jongbloed, Jan D H
AU - Hershberger, Ray E
AU - Morales, Ana
AU - Judge, Daniel P
AU - Syrris, Petros
AU - Pilichou, Kalliopi
AU - Medeiros Domingo, Argelia
AU - Murray, Brittney
AU - Cadrin-Tourigny, Julia
AU - Lekanne Deprez, Ronald
AU - Celeghin, Rudy
AU - Protonotarios, Alexandros
AU - Asatryan, Babken
AU - Brown, Emily
AU - Jordan, Elizabeth
AU - McGlaughon, Jennifer
AU - Thaxton, Courtney
AU - Kurtz, C Lisa
AU - van Tintelen, J Peter
N1 - Funding Information:
This work was financially supported by grants from the National Institutes of Health (NIH; U41HG009650) and by the Netherlands Cardiovascular Research Initiative (Dr van Tintelen) an initiative supported by the Dutch Heart Foundation (CVON2018-30 PREDICT2 and CVON 2015-12 eDETECT). The Johns Hopkins ARVD/C Program (Dr James and B. Murray) is supported by the Leonie-Wild Foundation, the Leyla Erkan Family Fund for ARVD Research, the Dr Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family, the Peter French Memorial Foundation, and the Wilmerding Endowments. Dr Syrris was supported by Fondation Leducq Transatlantic Networks of Excellence Program grant no 14CVD03 and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (United Kingdom). Dr Protonotarios is supported by a British Heart Foundation clinical research training fellowship grant (FS/18/82/34024).
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease characterized by ventricular arrhythmias and progressive ventricular dysfunction. Genetic testing is recommended, and a pathogenic variant in an ARVC-associated gene is a major criterion for diagnosis according to the 2010 Task Force Criteria. As incorrect attribution of a gene to ARVC can contribute to misdiagnosis, we assembled an international multidisciplinary ARVC Clinical Genome Resource Gene Curation Expert Panel to reappraise all reported ARVC genes. Methods: Following a comprehensive literature search, six 2-member teams conducted blinded independent curation of reported ARVC genes using the semiquantitative Clinical Genome Resource framework. Results: Of 26 reported ARVC genes, only 6 (PKP2, DSP, DSG2, DSC2, JUP, and TMEM43) had strong evidence and were classified as definitive for ARVC causation. There was moderate evidence for 2 genes, DES and PLN. The remaining 18 genes had limited or no evidence. RYR2 was refuted as an ARVC gene since clinical data and model systems exhibited a catecholaminergic polymorphic ventricular tachycardia phenotype. In ClinVar, only 5 pathogenic/likely pathogenic variants (1.1%) in limited evidence genes had been reported in ARVC cases in contrast to 450 desmosome gene variants (97.4%). Conclusions: Using the Clinical Genome Resource approach to gene-disease curation, only 8 genes (PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, and DES) had definitive or moderate evidence for ARVC, and these genes accounted for nearly all pathogenic/likely pathogenic ARVC variants in ClinVar. Therefore, only pathogenic/likely pathogenic variants in these 8 genes should yield a major criterion for ARVC diagnosis. Pathogenic/likely pathogenic variants identified in other genes in a patient should prompt further phenotyping as variants in many of these genes are associated with other cardiovascular conditions.
AB - Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease characterized by ventricular arrhythmias and progressive ventricular dysfunction. Genetic testing is recommended, and a pathogenic variant in an ARVC-associated gene is a major criterion for diagnosis according to the 2010 Task Force Criteria. As incorrect attribution of a gene to ARVC can contribute to misdiagnosis, we assembled an international multidisciplinary ARVC Clinical Genome Resource Gene Curation Expert Panel to reappraise all reported ARVC genes. Methods: Following a comprehensive literature search, six 2-member teams conducted blinded independent curation of reported ARVC genes using the semiquantitative Clinical Genome Resource framework. Results: Of 26 reported ARVC genes, only 6 (PKP2, DSP, DSG2, DSC2, JUP, and TMEM43) had strong evidence and were classified as definitive for ARVC causation. There was moderate evidence for 2 genes, DES and PLN. The remaining 18 genes had limited or no evidence. RYR2 was refuted as an ARVC gene since clinical data and model systems exhibited a catecholaminergic polymorphic ventricular tachycardia phenotype. In ClinVar, only 5 pathogenic/likely pathogenic variants (1.1%) in limited evidence genes had been reported in ARVC cases in contrast to 450 desmosome gene variants (97.4%). Conclusions: Using the Clinical Genome Resource approach to gene-disease curation, only 8 genes (PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, and DES) had definitive or moderate evidence for ARVC, and these genes accounted for nearly all pathogenic/likely pathogenic ARVC variants in ClinVar. Therefore, only pathogenic/likely pathogenic variants in these 8 genes should yield a major criterion for ARVC diagnosis. Pathogenic/likely pathogenic variants identified in other genes in a patient should prompt further phenotyping as variants in many of these genes are associated with other cardiovascular conditions.
KW - desmosomes
KW - diagnosis
KW - genes
KW - genetic testing
KW - tachycardia
UR - https://www.scopus.com/pages/publications/85108115711
U2 - 10.1161/CIRCGEN.120.003273
DO - 10.1161/CIRCGEN.120.003273
M3 - Article
C2 - 33831308
SN - 2574-8300
VL - 14
SP - 273
EP - 284
JO - Circulation. Genomic and precision medicine
JF - Circulation. Genomic and precision medicine
IS - 3
M1 - e003273
ER -